British American Tobacco's 8% EPS Push Still Leaves No Margin of Safety

BAT's latest beat improves the story, but not enough to make the stock cheap

The latest results make BAT look easier to like. But easier is not the same as forgiving.

Good news can make the risk look calmer than it is

First-half adjusted EPS growth of 7.9% was followed by management lifting full-year EPS guidance to the middle of its 5-8% target range. For yield investors, that kind of follow-through can feel reassuring precisely because the income stream also looks stable: BAT still pays quarterly dividend instalments of 61.26p. When earnings beat, guidance rises, and dividends remain in place, it is easy to read those signals as proof that the transition is settling down. They are not, not yet.

The issue is whether the market has already priced the execution

That is the real test now: has the stock already absorbed most of the good news? A company can deliver another quarter of discipline and still offer little margin of safety if investors are already assuming steady progress across U.S. categories, nicotine pouches, and the broader portfolio. The recent numbers are better. That does not automatically mean the valuation now rewards disappointment.

What the bull case is betting on

That guiding improvement in EPS only matters if investors keep believing the revenue mix is changing.

Why the transition looks more credible now

After first-half adjusted EPS growth of 7.9% and the move to the middle of its 5-8% target range, bulls are no longer relying on a pure hope story. They are pointing to a transition that looks more visible. The clearest upgrade is management raising its new-category annual revenue growth forecast to the mid-teens from low double-digits, helped by demand for vapes and nicotine pouches. That shifts the argument away from abstract innovation and closer to revenue contribution.

The valuation case depends on mix improving

The stronger bull argument is not just that new products are growing. It is that smokeables could change how BAT earns money over time. If newer categories expand faster, the business should rely less on a shrinking cigarette base to protect growth and margins. Management is also leaning on a potentially more supportive U.S. regulatory backdrop to help defend market share. If that plays out, the U.S. could do more than stabilise results; it could improve mix.

Optimism is the real risk in the current setup

Recent results have helped that case along. Adjusted earnings of 164p per share, above analyst forecasts of 158.5p give investors a fresh anchor. When a beat is followed by a guidance upgrade, it is natural to treat the latest quarter as proof that the strategy is working. But a better category-growth outlook is not the same as a fully de-risked business. Investors still need sustained evidence that newer categories and the U.S. can carry the company through ongoing pressure in traditional cigarette markets.

Why the old comfort trade may still be misleading

The debate is not whether BAT is improving. It is whether the current valuation still assumes more consistency than the business has earned.

Investors keep leaning on familiar support levels

Investors keep returning to familiar numbers: adjusted earnings of 164p per share, a beat versus expectations, and quarterly dividend instalments of 61.26p. That mix is psychologically comforting because it suggests the cash machine is still intact. But comfort is not the same as lower risk.

Reuters also described the terminal decline of traditional cigarettes, while noting that stronger new-category and U.S. performance had to offset a sharp decline in Asia. That is not the profile of a fully de-risked compounder. It is a company in transition, with structural pressure in its legacy base.

A better growth forecast still comes with caveats

Management has raised its new-category annual revenue growth forecast to the mid-teens, and that deserves attention. But the same report tied part of the outlook to betting on easing FDA enforcement to boost its U.S. market share. That is a helpful tailwind, not proof of commercial resilience on its own.

Yield can make investors tolerate more risk than they should

Income-focused investors are less eager to give up quarterly dividend instalments of 61.26p, so they may accept more operating risk than they would around a cleaner growth story. That can help support a stock even when the underlying mix still needs to prove it can hold up.

If Asia weakens again or the regulatory backdrop does not improve as expected, the new-category story may remain compelling without becoming strong enough to protect the valuation.

What would change the view

My call has not turned bullish. It has become more conditional: I would rather own BAT after evidence that the newer growth claims are holding, rather than chase the stock after a beat aided by quarterly dividend instalments.

The signals that matter next

• Execution in reported results: The robust demand for vapes and nicotine pouches needs to keep showing up in reported performance, not just in the upgraded growth outlook.
• U.S. traction, not just a supportive backdrop: Investors need to see whether easing FDA enforcement helps boost its U.S. market share in a durable way.
• A less one-sided offset burden: Last time, surging demand for its Velo nicotine pouches and a strong U.S. performance offset a sharp decline in Asia. If that balance improves, confidence in the story can increase.

What would break the current setup

• Asia slips again while the new-category lift loses momentum.
• The FDA angle remains a helpful backdrop rather than translating into commercial traction.
• The payout stays intact, but the revenue mix does not improve enough to reduce the underlying risk.

The practical view is straightforward: BAT looks more interesting after proof of execution than after a good quarter alone.